CARDIOGENESIS ANNOUNCES SUCCESSFUL CLINICAL APPLICATION OF PHOENIX TMR PLUS STEM CELL DELIVERY SYSTEM
Cardiogenesis Corporation, the market leader in surgical products and accessories
used in angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous
Myocardial Channeling (PMC) procedures announced today the first clinical surgical
cardiac revascularization procedure completed on January 25, 2006 by Dr. Wan
Feng, Chairman of the Department of Cardiac Surgery at The People's Hospital
of Beijing University with its PHOENIX Revascularization Delivery System for
precise delivery of stem cells in conjunction with Holmium.